Zobrazeno 1 - 10 of 52 pro vyhledávání: '"Kristin R. Wildsmith"'
1
Akademický článek
Evaluation of partial volume correction and analysis of longitudinal [18F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models
Autor: Sandra M. Sanabria Bohórquez, Suzanne Baker, Paul T. Manser, Matteo Tonietto, Christopher Galli, Kristin R. Wildsmith, Yixuan Zou, Geoffrey A. Kerchner, Robby Weimer, Edmond Teng
Publikováno v: Frontiers in Neuroimaging, Vol 3 (2024)
PurposeWe evaluated the impact of partial volume correction (PVC) methods on the quantification of longitudinal [18F]GTP1 tau positron-emission tomography (PET) in Alzheimer's disease and the suitability of describing the tau pathology burden tempora
Externí odkaz: https://doaj.org/article/935c608a68ca4a409b94bd58178354e4
Zobrazit plný text záznamu
2
Akademický článek
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
Autor: Edmond Teng, Paul T. Manser, Sandra Sanabria Bohorquez, Kristin R. Wildsmith, Karen Pickthorn, Suzanne L. Baker, Michael Ward, Geoffrey A. Kerchner, Robby M. Weimer
Publikováno v: Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer’s disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [18F]GTP1 tau PET an
Externí odkaz: https://doaj.org/article/151ea849eff2427ead44ea9980aa2f28
Zobrazit plný text záznamu
3
Akademický článek
Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays
Autor: Stephen P. Schauer, William R. Mylott, Moucun Yuan, Rand G. Jenkins, W. Rodney Mathews, Lee A. Honigberg, Kristin R. Wildsmith
Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-16 (2018)
Abstract Background Amyloid-β 1–42 (Aβ1–42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ1–42 are indicative of AD, but significant variation in the absolute concentrat
Externí odkaz: https://doaj.org/article/3e6fd5011dbc47cfa8ce4866df171628
Zobrazit plný text záznamu
4
Akademický článek
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
Autor: Stephen Salloway, Lee A. Honigberg, William Cho, Michael Ward, Michel Friesenhahn, Flavia Brunstein, Angelica Quartino, David Clayton, Deborah Mortensen, Tobias Bittner, Carole Ho, Christina Rabe, Stephen P. Schauer, Kristin R. Wildsmith, Reina N. Fuji, Shehnaaz Suliman, Eric M. Reiman, Kewei Chen, Robert Paul
Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-13 (2018)
Abstract Background We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moder
Externí odkaz: https://doaj.org/article/a311ee7ca9264e6696bffa8520f93ab9
Zobrazit plný text záznamu
6
Safety and Efficacy of Semorinemab in Individuals with Prodromal to Mild Alzheimer Disease
Autor: Edmond, Teng, Paul T, Manser, Karen, Pickthorn, Flavia, Brunstein, Mira, Blendstrup, Sandra, Sanabria Bohorquez, Kristin R, Wildsmith, Bali, Toth, Michael, Dolton, Vidya, Ramakrishnan, Ashwini, Bobbala, Sietske A M, Sikkes, Michael, Ward, Reina N, Fuji, Geoffrey A, Kerchner, David, Weisman
Publikováno v: JAMA Neurology, 79(8), 758-767. American Medical Association
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals with Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375
Importance: Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to am
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5221ef4dd6e70490909446ed6b1ce80
http://www.scopus.com/inward/record.url?scp=85132835366&partnerID=8YFLogxK
Zobrazit plný text záznamu
7
Translational Approaches for Brain Delivery of Biologics via Cerebrospinal Fluid
Autor: Shraddha S, Sadekar, Mayumi, Bowen, Hao, Cai, Samira, Jamalian, Hanine, Rafidi, Whitney, Shatz-Binder, Julien, Lafrance-Vanasse, Pamela, Chan, William J, Meilandt, Amy, Oldendorp, Alavattam, Sreedhara, Ann, Daugherty, Susan, Crowell, Kristin R, Wildsmith, Jasvinder, Atwal, Reina N, Fuji, Joshua, Horvath
Publikováno v: Clinical Pharmacology & Therapeutics. 111:826-834
Delivery of biologics via cerebrospinal fluid (CSF) has demonstrated potential to access the tissues of the central nervous system (CNS) by circumventing the blood-brain barrier and blood-CSF barrier. Developing an effective CSF drug delivery strateg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd4af582ed8aa4819475cceff982f1d
https://doi.org/10.1002/cpt.2531
Zobrazit plný text záznamu
8
Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
Autor: Kristin R. Wildsmith, Randall J. Bateman, Paul T. Manser, Balazs Toth, Sandra M. Sanabria-Bohórquez, Nicolas R. Barthélemy, Michael Keeley, Edmond Teng, Robby M. Weimer
Publikováno v: Journal of Alzheimer's Disease. 85:415-429
Background: Understanding patterns of association between CSF phosphorylated tau (p-tau) species and clinical disease severity will aid Alzheimer’s disease (AD) diagnosis and treatment. Objective: To evaluate changes in tau phosphorylation ratios t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95a0bea7962fd4765cc9818dc811bda4
https://doi.org/10.3233/jad-210677
Zobrazit plný text záznamu
9
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
Autor: Kristin R. Wildsmith, Geoffrey A. Kerchner, Michael Ward, Edmond Teng, Paul T. Manser, Suzanne L. Baker, Karen Pickthorn, Sandra Sanabria Bohorquez, Robby M. Weimer
Publikováno v: Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-14 (2021)
Alzheimer's research & therapy, vol 13, iss 1
Alzheimer's Research & Therapy
Background The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer’s disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [18F]GTP1 tau PET and subsequ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9dfe74821e4dd458e22a73b8d8a8999
https://doaj.org/article/151ea849eff2427ead44ea9980aa2f28
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje